The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Daily Treatment with SMTC1100, a Novel Small Molecule Utrophin Upregulator, Dramatically Reduces the Dystrophic Symptoms in the mdx Mouse
Open accessAbstract
BACKGROUND: Duchenne muscular dystrophy (DMD) is a lethal, progressive muscle wasting disease caused by a loss of sarcolemmal bound dystrophin, which results in the death of the muscle fibers leading to the gradual depletion of skeletal muscle. There is significant evidence demonstrating that increasing levels of the dystrophin-related protein, utrophin, in mouse models results in sarcolemmal bound utrophin and prevents the muscular dystrophy pathology. The aim of this work was to develop a small molecule which increases the levels of utrophin in muscle and thus has therapeutic potential. METHODOLOGY AND PRINCIPAL FINDINGS: We describe the in vivo activity of SMT C1100; the first orally bioavailable small molecule utrophin upregulator. Once-a-day daily-dosing with SMT C1100 reduces a number of the pathological effects of dystrophin deficiency. Treatment results in reduced pathology, better muscle physiology leading to an increase in overall strength, and an ability to resist fatigue after forced exercise; a surrogate for the six minute walk test currently recommended as the pivotal outcome measure in human trials for DMD. CONCLUSIONS AND SIGNIFICANCE: This study demonstrates proof-of-principle for the use of in vitro screening methods in allowing identification of pharmacological agents for utrophin transcriptional upregulation. The best compound identified, SMT C1100, demonstrated significant disease modifying effects in DMD models. Our data warrant the full evaluation of this compound in clinical trials in DMD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacological strategies for muscular dystrophy
Khurana, T. S., & Davies, K. E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1085 · Cited by 225
Self-citation
Cited by
The DisGeNET knowledge platform for disease genomics: 2019 update
Piñero, J., Ramírez-Anguita, J. M., Saüch-Pitarch, J., Ronzano, F., Centeno, E., Sanz, F., & Furlong, L. I. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1021 · Cited by 2,639
Mercuri, E., & Muntoni, F. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61897-2 · Cited by 434
Allen, D. G., Whitehead, N. P., & Froehner, S. C. (2016) · Physiological Reviews · doi:10.1152/physrev.00007.2015 · Cited by 426
The Pathogenesis and Therapy of Muscular Dystrophies
Guiraud, S., Aartsma-Rus, A., Vieira, N. M., Davies, K. E., van Ommen, G.-J. B., & Kunkel, L. M. (2015) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090314-025003 · Cited by 302
Self-citationDuchenne Muscular Dystrophy: From Diagnosis to Therapy
Falzarano, M., Scotton, C., Passarelli, C., & Ferlini, A. (2015) · Molecules · doi:10.3390/molecules201018168 · Cited by 292
Metadata
- Authors
- Tinsley, J. M., Fairclough, R. J., Storer, R., Wilkes, F. J., Potter, A. C., Squire, S. E., Powell, D. S., Cozzoli, A., Capogrosso, R. F., Lambert, A., Wilson, F. X., Wren, S. P., De Luca, A., & Davies, K. E.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-05-06
- Volume
- 6
- Issue
- 5
- Pages
- e19189
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2155995223
- Cited by
- 185
- References
- 1
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Daily Treatment with SMTC1100, a Novel Small Molecule Utrophin Upregulator, Dramatically Reduces the Dystrophic Symptoms in the mdx Mouse. https://app.cochat.ai/papers/10.1371/journal.pone.0019189
- The paper
- Tinsley, J. M., Fairclough, R. J., Storer, R., Wilkes, F. J., Potter, A. C., Squire, S. E., Powell, D. S., Cozzoli, A., Capogrosso, R. F., Lambert, A., Wilson, F. X., Wren, S. P., De Luca, A., & Davies, K. E. (2011). Daily Treatment with SMTC1100, a Novel Small Molecule Utrophin Upregulator, Dramatically Reduces the Dystrophic Symptoms in the mdx Mouse. PLoS ONE. https://doi.org/10.1371/journal.pone.0019189
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.